- Home
- IMMX vs XTNT Comparison
IMMX vs XTNT Comparison
Compare IMMX & XTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- XTNT
- Stock Information
- Founded
- IMMX 2014
- XTNT N/A
- Country
- IMMX United States
- XTNT United States
- Employees
- IMMX N/A
- XTNT N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- XTNT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMMX Health Care
- XTNT Health Care
- Exchange
- IMMX Nasdaq
- XTNT Nasdaq
- Market Cap
- IMMX 61.1M
- XTNT 60.9M
- IPO Year
- IMMX 2021
- XTNT N/A
- Fundamental
- Price
- IMMX $2.13
- XTNT $0.73
- Analyst Decision
- IMMX Strong Buy
- XTNT
- Analyst Count
- IMMX 1
- XTNT 0
- Target Price
- IMMX $7.00
- XTNT N/A
- AVG Volume (30 Days)
- IMMX 261.4K
- XTNT 74.4K
- Earning Date
- IMMX 08-11-2025
- XTNT 08-07-2025
- Dividend Yield
- IMMX N/A
- XTNT N/A
- EPS Growth
- IMMX N/A
- XTNT N/A
- EPS
- IMMX N/A
- XTNT N/A
- Revenue
- IMMX N/A
- XTNT $122,298,000.00
- Revenue This Year
- IMMX N/A
- XTNT $11.64
- Revenue Next Year
- IMMX N/A
- XTNT $7.59
- P/E Ratio
- IMMX N/A
- XTNT N/A
- Revenue Growth
- IMMX N/A
- XTNT 20.81
- 52 Week Low
- IMMX $1.26
- XTNT $0.33
- 52 Week High
- IMMX $3.00
- XTNT $0.83
- Technical
- Relative Strength Index (RSI)
- IMMX 45.97
- XTNT 67.35
- Support Level
- IMMX $2.16
- XTNT $0.60
- Resistance Level
- IMMX $2.31
- XTNT $0.78
- Average True Range (ATR)
- IMMX 0.17
- XTNT 0.05
- MACD
- IMMX -0.04
- XTNT 0.01
- Stochastic Oscillator
- IMMX 11.14
- XTNT 85.71
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About XTNT Xtant Medical Holdings Inc.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.